SBIR-STTR Award

Drug therapy for hypercalcemia/bone resorption
Profile last edited on: 2/27/02

Program
SBIR
Agency
NIH | NIAMS
Total Award Amount
$50,000
Award Phase
1
Principal Investigator
Carlos M Samour
Activity Indicator

Company Information

Macrochem Corporation (AKA:MCHM)

110 Hartwell Avenue
Lexington, MA 02421
   (781) 862-4003
   info@macrochem.com
   www.macrochem.com
Multiple Locations:   
Congressional District:   05
County:   Middlesex

Phase I

Phase I year
1988
Phase I Amount
$50,000
Current drug therapy for hypercalcemic diseases involving bone resorption is of limited effectiveness. Preliminary animal testing has shown benzo(b)thiophene-2-carboxylic acid (thionapthenecarboxylic acid, TNCA) to be of potential use in inhibiting bone resorption. Overall project goals are to develop TNCA and its derivatives as novel therapeutic entities in the treatment of hypercalcemia of malignancy, hypercalcemia of primary hyperparathyroidism, Paget's Disease, arthritis a osteoporosis. TNCA's us application potentially extends to bone calcium loss suffered in stratospheric residence.Specific Phase I activities include the testing of a novel water- soluble derivative of TNCA in a number of in vivo biological test systems, such as rats with Leydig cell tumors and Walker 256 carcinosarcomas. Animals will be evaluated for survival, bone changes, and toxic effects. Selected animals will be examined histologically for changes in bone resorption based upon the number of osteoclasts and resorption lacunae. In addition, several new and novel tetracycline and phosphonate derivatives will be synthesized and evaluated in a tissue culture test model of bone cells. The new derivatives will also be tested in tissue culture models.National Institute of Arthritis and Musculosketal and Skin Diseases (NIAMS)

Phase II

Phase II year
---
Phase II Amount
---